Intraportal delivery of immunosuppression to intrahepatic islet allograft recipients

Transplant International : Official Journal of the European Society for Organ Transplantation
X WangD C Dafoe

Abstract

Local delivery of immunosuppressive agents may dampen local alloreactive events with avoidance of systemic toxicity. We investigated the innovative strategy of intraportal (IPO) delivery of three immunosuppressive agents in streptozotocin diabetic rat recipients of islet allografts (Lewis to Wistar-Furth) transplanted intrahepatically. IPO budesonide (BUD, 240 or 360 micrograms/kg per day), a potent steroid, and cyclosporin (CyA, 2 or 4 mg/kg per day) did not prolong graft mean survival time [MST +/- standard deviation (SD)] as compared to nonimmunosuppressed recipients. Fourteen days of IPO FK 506 (0.16 mg/kg per day) significantly increased MST as compared with untreated controls (49 +/- 29 vs 7 +/- 1 days, P < 0.01) and was more effective than intravenous (IV) FK 506 (17 +/- 7 days, P < 0.01). When FK 506 was given for 28 days, the benefit of IPO over IV delivery was reaffirmed (MST 81 +/- 32 vs 34 +/- 4 days, P < 0.01). The potential for toxicity was lessened by lower mean systemic levels in the IPO group as compared to the IV group (1.3 +/- 0.6 vs 3.5 +/- 0.9 ng/mg, P < 0.02). The strategy of continuous IPO FK 506 was effective in the prevention of rejection of intrahepatic islet allografts.

References

Jul 1, 1992·Transplantation·S A Gruber
Jan 1, 1990·Transplantation·M P CalleryM W Flye
Dec 21, 1989·The New England Journal of Medicine·B D Kahan
Dec 1, 1988·Transplantation·T J RuersW A Buurman
Jan 1, 1986·Transplantation·H J HahnR Warzock
Jun 1, 1974·The Journal of Surgical Research·M M ZieglerC F Barker
Mar 1, 1983·Transplantation·N L AscherR L Simmons
Jul 1, 1984·Transplantation·P Häyry

❮ Previous
Next ❯

Citations

Mar 12, 2013·Clinical & Developmental Immunology·Jonas T SchniderVijay S Gorantla
Feb 25, 2011·Journal of Investigative Surgery : the Official Journal of the Academy of Surgical Research·Melanie L GrahamHenk-Jan Schuurman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Journal of Visual Communication in Medicine
Garry Swann
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
Eckart BertelmannUwe Pleyer
Journal of Anaesthesiology, Clinical Pharmacology
Anju Gupta, Nishkarsh Gupta
© 2021 Meta ULC. All rights reserved